Analyst Reco. Neurogene Inc.

Equities

NGNE

US64135M1053

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 06/03/2026 GMT			5-day change	1st Jan Change
22.17 ^USD	+0.18%		-5.62%	+7.62%

03-03	Neurogene announces inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
02-26	Neurogene announces FDA breakthrough therapy designation for NGN-401 gene therapy for Rett syndrome	RE

Analyst Reco.

11-13	Gene therapy developer Neurogene's Q3 net loss widens	RE
09/10/25	Neurogene Plans to Initiate Dosing in Registrational Trial in Q4 2025	MT
16/05/25	Neurogene Shares Drop After Downgrade From Baird	MT
16/05/25	Baird Downgrades Neurogene to Neutral From Outperform, Adjusts Price Target to $24 From $38	MT
27/06/24	BMO Initiates Neurogene at Outperform With $65 Price Target	MT
11/06/24	Baird Initiates Neurogene With Outperform Rating, $54 Price Target	MT
29/04/24	Leerink Partners Starts Neurogene With Outperform Rating, $46 Price Target	MT
21/03/24	William Blair Initiates Neurogene With Outperform Rating	MT
08/01/24	HC Wainwright Starts Neurogene With Buy Rating, $45 Price Target	MT
05/01/24	Stifel Starts Coverage on Neurogene with Buy Rating, $31 Price Target	MT
09/05/23	Mizuho Adjusts Price Target on Neoleukin Therapeutics to $1.50 From $2, Keeps Neutral Rating	MT
03/01/23	Guggenheim Downgrades Neoleukin Therapeutics to Neutral From Buy	MT
15/11/22	Mizuho Downgrades Neoleukin Therapeutics to Neutral From Buy, Adjusts Price Target to $2 From $21	MT
15/11/22	Canaccord Genuity Downgrades Neoleukin Therapeutics to Hold From Buy, Adjusts Price Target to $1 From $10	MT
12/09/22	BofA Securities Downgrades Neoleukin Therapeutics to Underperform From Buy, Adjusts Price Target to $1 From $3	MT
12/09/22	HC Wainwright Adjusts Neoleukin Therapeutics' Price Target to $6 from $22, Maintains Buy Rating	MT
10/08/22	Stifel Nicolaus Adjusts Price Target for Neoleukin Therapeutics to $14 From $18, Maintains Buy Rating	MT
06/07/22	Canaccord Genuity Assumes Neoleukin Therapeutics at Buy with $10 Price Target	MT
31/05/22	Piper Sandler Adjusts Price Target on Neoleukin Therapeutics to $6 From $25, Reiterates Overweight Rating	MT
10/05/22	Guggenheim Adjusts Price Target for Neoleukin Therapeutics to $12 From $16, Maintains Buy Rating	MT
02/03/22	Piper Sandler Adjusts Neoleukin Therapeutics Price Target to $25 From $30, Maintains Overweight Rating	MT
06/08/21	NEOLEUKIN THERAPEUTICS : Piper Sandler Starts Neoleukin Therapeutics at Overweight with $30 Price Target	MT
06/01/21	NEOLEUKIN THERAPEUTICS : Stifel Starts Neoleukin Therapeutics at Buy With $18 Price Target	MT